FDA allows Philip Morris' Zyn nicotine pouches to claim lower health risks than cigarettes

The FDA has authorized 20 Zyn nicotine pouch products, owned by Philip Morris, to carry a modified-risk claim stating that switching from cigarettes to Zyn lowers the risk of several smoking-related diseases such as mouth cancer and heart disease. This regulatory approval marks a significant marketing advantage for Philip Morris amid declining cigarette sales and growing popularity of smoke-free nicotine products. However, the FDA emphasizes that Zyn is not safe and discourages tobacco use among youth and non-users. The decision reflects a broader shift under the current administration toward more industry-friendly policies on nicotine alternatives.